A Study of Trametinib and GSK2141795 Multiple Myeloma

Official Title

A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma


This is a phase 2 study to see how useful investigational drug trametinib is, with or without GSK2141795, in patients with patients with multiple myeloma whose cancer as come back or there are no standard treatments available for treatment of their disease.

Trial Description

Primary Outcome Measures:

  • ORR evidenced by confirmed response rate, defined as partial response or better by International Myeloma Working Group (IMWG) criteria
    The patient will be classified as having had a response if he/she has a confirmed response (i.e., a stringent complete response, or complete response or near complete response or very good partial response or partial response noted as the objective status of two consecutive assessments). The rate of minimal response (MR) and PD will also be observed.
Secondary Outcome Measures:
  • PFS
  • DOR
  • ORR after the addition of AKT inhibitor GSK2141795 to trametinib in patients who have developed progressive disease or have achieved less than a PR
  • Incidence of adverse event reactions reported according to CTCAE v4.0
  • Reported by type, frequency, and severity.
Other Outcome Measures:
  • Pharmacodynamic markers of trametinib
  • Quantification of MAF expression by qPCR and FISH
  • Chromosomal abnormalities as determined by FISH
  • Cell surface expression of integrin beta 7 determined by flow cytometry on cluster of differentiation (CD)138 positive myeloma cells derived from screening bone marrow samples
  • Tumour mutational profile by sequenom analysis
  • Change in PI3K/AKT activation determined by phospho-flow cytometry and reversal phase protein arrays (RPPA)
  • Change in RAS-MEK-ERK activation determined by phospho-flow cytometry and RPPA


  • To evaluate the antitumor activity of trametinib determined by overall response rate (ORR) in patients that are stratified into grouped based on: biomarker positive (neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog [KRAS], v-raf murine sarcoma viral oncogene homolog B1 [BRAF] mutated) and biomarker negative (without NRAS, KRAS, BRAF mutation).


  • To evaluate progression free survival (PFS) and duration of response (DOR) in the two stratified groups.
  • To document ORR after the addition of GSK2141795 (Akt inhibitor GSK2141795) to trametinib in patients who have developed progressive disease or have achieved less than a partial response (PR) after 4 cycles of treatment.
  • To evaluate PFS and DOR in patients receiving trametinib plus GSK2141795. IV. To evaluate the safety profile of trametinib with and without GSK2141795.


  • To explore the relationship between clinical response and pharmacodynamic (PD) markers.
  • To explore the relationship between v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF) expression as determined by quantitative polymerase chain reaction (qPCR), chromosomal abnormalities detected by florescence in situ hybridization (FISH), and clinical response.
  • To explore the role of integrin beta7 as a biomarker of MAF expression.
  • To explore the relationship between objective clinical response as well as progressive disease and the tumor mutational profile.
  • To explore mechanism of phosphatidylinositol 3 kinase (PI3K)/v-akt Murine Thymoma Viral Oncogene Homolog 1 (AKT) and retrovirus-associated deoxyribonucleic acid (DNA) sequence (RAS)-mitogen-activated protein kinase kinase (MEK)-mitogen-activated protein kinase 1 (ERK) activation and correlate these with clinical response and PD markers.


Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.

After completion of study treatment, patients are followed up for 4 weeks.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society